Article 1 to 3 out of 3 concerning JADO Technologies GmbH
Jado initiates phase II trails of lead RAFT modulator in urticaria(07/04/2008) JADO Technologies GmbH, a developer of RAFT intervention therapeutics, announced the start of a Phase II study to evaluate the safety and efficacy of oral TF002, a formulation of miltefosine, in patients with antihistamine resistant urticaria. TF002 ...
JADO reports clinical proof of concept with RAFT modulator in atopic dermatitis(02/21/2008) JADO Technologies GmbH, developer of RAFT intervention therapeutics, announced positive results from a Phase IIa clinical trial of its lead RAFT modulator TF002 in patients with severe atopic dermatitis. TF002, a topical formulation of miltefosine, ...
Top
